 WATERTOWN, Mass., March 10, 2021 GLOBE NEWSWIRE -- C4 Therapeutics, Inc. C4T Nasdaq: CCC, a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that a late-breaking abstract featuring preclinical data for CFT7455 has been selected for presentation at the first session of the American Association for Cancer Research AACR 2021 Annual Meeting, being held virtually April 10-15, 2021. CFT7455, the Companys most advanced protein degrader, targets IKZF13 for the treatment of hematologic malignancies. 